A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination
Open Access
- 15 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cureus
- Vol. 13 (5)
- https://doi.org/10.7759/cureus.15035
Abstract
Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes, and it can be either idiopathic or secondary to a coexisting disorder. In this report, we present a case of a patient who suffered from acute and severe AIHA after receiving the second dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine.This publication has 4 references indexed in Scilit:
- The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 PandemicInternational Journal of Molecular Sciences, 2020
- COVID‐19 associated with severe autoimmune hemolytic anemiaTransfusion, 2020
- New Insights in the Pathogenesis of Autoimmune Hemolytic AnemiaTransfusion Medicine and Hemotherapy, 2015
- Autoimmune Hemolytic Anemia Following Influenza Virus Infection or Administration of Influenza VaccineJournal of Blood Disorders & Transfusion, 2014